In value terms, private equity deal activity increased by 111% in Q2 2023 compared with the previous quarter’s total of $8.2bn and rose by 287% as compared to Q2 2022. Related deal volume increased by 33% in Q2 2023 versus the previous quarter and was 70% higher than in Q2 2022.
Notably, foreign direct investments (fdi)-related deals accounted for a 41% share of the global pharmaceutical industry’s private equity deal activity in Q2 2023, up 52% over the previous quarter.
The top-ranked financial advisors supporting these private equity deals in Q2 2023 were Cantor Fitzgerald; Moelis & Co; UBS Group with 4, 4, 4 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Q2 2023 were Kirkland & Ellis; Baker & McKenzie; Goodwin Procter with 7, 5, 5 deals respectively.
For further understanding of GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.